文献速递前列腺癌

高危前列腺癌新辅助新型内分泌治疗联合前列腺根治术对比即刻前列腺根治术的对照分析

Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
PubMed 文献 · J Urol · 2022-09-09

该研究比较高危前列腺癌患者接受新型内分泌药物(NHA)新辅助治疗后再行根治性前列腺切除术(neo-RP,112例)与即刻根治性前列腺切除术(RP,259例)的结局;经逆概率治疗加权后,neo-RP组至生化复发时间(HR=0.25,95%CI 0.18-0.37)和无转移生存期(HR=0.26,95%CI 0.15-0.46)均显著优于RP组。

要点

  • 高危前列腺癌新辅助NHA后RP较即刻RP与更长的至生化复发时间相关(HR=0.25)。
  • 高危前列腺癌新辅助NHA后RP较即刻RP与更优的无转移生存期相关(HR=0.26)。
  • neo-RP组辅助治疗率(7% vs 24%)和挽救治疗率(34% vs 46%)均低于RP组。

核心结论

  • 在高危前列腺癌男性中,根治性前列腺切除术前采用NHA新辅助治疗与更长的至生化复发时间和更优的无转移生存期相关,相较于即刻根治性前列腺切除术。
  • 这些发现具有假说生成性,但提示NHA新辅助治疗在高危前列腺癌中可能获益,该策略目前正在3期PROTEUS试验(NCT03767244)中研究。

研究设计与样本

  • neo-RP队列由3项NHA新辅助治疗后行RP试验中的高危前列腺癌患者组成(112例)。
  • RP组为2010-2016年在本机构接受无新辅助治疗的RP、且符合新辅助试验关键入选标准(即≥3个阳性活检针和Gleason≥4+3=7)的高危前列腺癌观察性队列(259例)。
  • 采用逆概率治疗加权(IPTW)以最小化估计治疗效应时的潜在混杂因素。

主要发现

  • IPTW前,neo-RP队列的Gleason 9-10癌比例(46% vs 24%)、cT3疾病比例(22% vs 5%)和PSA≥20 ng/ml比例(14% vs 7%)均高于RP组;IPTW后两队列均衡。
  • IPTW后,neo-RP组至生化复发时间(HR=0.25 [95%CI 0.18-0.37])显著长于RP组。
  • IPTW后,neo-RP组无转移生存期(HR=0.26 [95%CI 0.15-0.46])显著优于RP组。
  • neo-RP组辅助治疗率(7% vs 24%)和挽救治疗率(34% vs 46%)均低于RP组。

临床怎么用

  • 原文结论指出这些发现具有假说生成性,但提示NHA新辅助治疗在高危前列腺癌中可能获益,该策略目前正在3期PROTEUS试验(NCT03767244)中研究。

局限性

  • 原文结论称这些发现具有假说生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to compare outcomes between neoadjuvant therapy with a novel hormonal agent (NHA) prior to radical prostatectomy (neo-RP) and up-front radical prostatectomy (RP) in patients with high-risk prostate cancer (HRPC). MATERIALS AND METHODS: HRPC patients treated on 3 trials of neoadjuvant NHA followed by RP formed the neo-RP cohort (112). The RP group (259) comprised an observational cohort of HRPC patients undergoing RP without neoadjuvant therapy between 2010-2016 at our institution who met key eligibility criteria for the neoadjuvant trials (ie ≥3 positive biopsy cores and Gleason ≥4+3=7). Inverse probability of treatment weighting (IPTW) was used to minimize potential confounding factors when estimating treatment effects. The primary outcomes were time to biochemical recurrence (BCR) and metastasis-free survival (MFS). RESULTS: Before IPTW, the neo-RP cohort had higher rates of Gleason 9-10 cancer (46% vs 24%), cT3 disease (22% vs 5%), and PSA ≥20 ng/ml (14% vs 7%); after IPTW, the 2 cohorts were balanced. Overall, after IPTW, time to BCR (HR=0.25 [95% CI 0.18-0.37]) and MFS (HR=0.26 [0.15-0.46]) were significantly longer in the neo-RP compared to the RP cohort. Rates of adjuvant (7% vs 24%) and salvage therapy (34% vs 46%) were lower in the neo-RP cohort. CONCLUSIONS: Neoadjuvant therapy with an NHA prior to RP was associated with longer time to BCR and superior MFS compared to up-front RP in men with HRPC. These findings are hypothesis-generating but suggest benefit with neoadjuvant therapy with an NHA in HRPC, an approach which is currently being studied in the phase 3 PROTEUS trial (NCT03767244).

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Ravi P, Kwak L, Xie W, et al. Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis. J Urol. 2022. PMID: 36082554. doi:10.1097/JU.0000000000002803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。